Asthma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators), By Product (Inhalers (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers), Nebulizers), By Route of Administration (Oral, Inhaled, Others), By Region and Competition, 2020-2030F

Market Overview

The Global Asthma Therapeutics Market will grow from USD 27.52 Billion in 2024 to USD 34.3 Billion by 2030 at a 3.74% CAGR. Asthma therapeutics encompass a range of pharmaceutical medications and treatment modalities designed to manage and alleviate the symptoms of asthma, a chronic respiratory condition characterized by airway inflammation and narrowing. The market's growth is primarily driven by the escalating global prevalence of asthma, particularly in urbanized regions, and the increasing awareness regarding disease management. Additionally, advancements in diagnostic technologies and robust research and development activities aimed at innovative drug formulations, including biologics and combination therapies, significantly support market expansion.

According to the Global Initiative for Asthma, in 2024, asthma affected over 260 million individuals worldwide, underscoring the substantial global patient population requiring therapeutic intervention. However, a significant challenge impeding market expansion is the high cost associated with advanced biologic therapies, which can limit patient access in various healthcare systems.

Key Market Drivers

The increasing global asthma prevalence significantly propels the demand for therapeutics. A growing number of individuals worldwide are diagnosed with this chronic respiratory condition, necessitating long-term management and various treatment interventions. This expanding patient population inherently broadens the market for existing medications and drives the need for new therapeutic developments. Factors such as urbanization, increased exposure to environmental allergens, and lifestyle changes contribute to the rising incidence of asthma across diverse demographics. According to the Global Initiative for Asthma, on World Asthma Day 2024, it was reported that asthma affects over 260 million people worldwide, highlighting the substantial patient base requiring therapeutic care. This pervasive health burden underscores the continuous requirement for effective asthma management solutions.

Advancements in asthma treatment options represent another pivotal driver, continuously reshaping the therapeutic landscape through innovation in drug development and delivery. Pharmaceutical research and development efforts are concentrated on introducing novel biologics and targeted therapies that address specific inflammatory pathways, offering improved efficacy and personalized approaches, particularly for severe or uncontrolled asthma. For instance, according to AstraZeneca, in May 2024, the company presented 59 abstracts at the American Thoracic Society International Conference, showcasing progress in its respiratory portfolio and highlighting ongoing research into new treatments. These innovations enhance treatment outcomes and expand the range of available medications. Furthermore, significant industry investments support this evolution; according to Fierce Pharma, in November 2025, AstraZeneca invested an additional $136 million into expanding its inhalants production base in China, demonstrating sustained commitment to advancing respiratory care solutions.

Download Free Sample Report

Key Market Challenges

The high cost associated with advanced biologic therapies represents a significant challenging factor for the global asthma therapeutics market. This elevated pricing directly impacts patient access, particularly in diverse healthcare systems where reimbursement policies or individual financial capacities may be restrictive. Consequently, a substantial portion of the patient population requiring these advanced treatments may face barriers to obtaining them, thereby limiting the overall market penetration and expansion of these innovative therapies.

This affordability issue directly hampers the market's growth potential. According to data published in the Journal of Asthma and Allergy in October 2024, an analysis of the International Severe Asthma Registry (ISAR) involving 9,587 patients across 21 countries indicated that 31.7% were classified as inaccessible to biologic therapies. This considerable segment of the severe asthma population, unable to access such treatments due to cost, translates into unrealized market demand and restricts the volume of biologic sales. The industry's ability to capitalize on the therapeutic benefits and advancements in biologics is thus constrained by these economic impediments to patient uptake.

Key Market Trends

The Global Asthma Therapeutics Market is significantly influenced by two distinct and impactful trends: the integration of digital health and smart inhaler technologies, and the growing adoption of advanced combination therapies. These trends reshape patient management and treatment strategies.

**Integration of Digital Health and Smart Inhaler Technologies**
This trend transforms asthma management via real-time data and enhanced medication adherence. Digital health platforms and smart inhalers, with sensors, monitor usage and technique, directly improving treatment efficacy. Over 35 million people in the U.S. lived with a chronic lung condition in 2023, as reported by the American Lung Association in September 2024, highlighting the need for these solutions. Such integration enables personalized adjustments and better patient-provider communication. For example, Adherium announced in April 2024 that its Hailie Smartinhaler received FDA clearance for AstraZeneca’s Airsupra and Breztri inhalers, providing real-time medication usage insights. These advancements drive demand for technologically integrated therapeutics.

**Growing Adoption of Advanced Combination Therapies**
The increasing preference for advanced combination therapies marks a major shift in asthma treatment, leading to comprehensive symptom control. These fixed-dose inhalers combine multiple active pharmaceutical ingredients, simplifying regimens and improving compliance by addressing both inflammation and bronchoconstriction. The Global Initiative for Asthma's 2024 update advises all adults and adolescents with asthma receive inhaled corticosteroid-containing medication, with the preferred reliever being as-needed low-dose ICS-formoterol combination. This industrial association directive highlights the move away from SABA-only treatment. A meta-analysis presented in November 2024 at the American College of Allergy, Asthma, and Immunology Annual Scientific Meeting showed rescue inhalers combining inhaled corticosteroids with formoterol reduced severe exacerbations by 10.3%. This clinical superiority fuels the market's embrace of combination approaches.

Segmental Insights

The Combination Therapy segment is recognized as the fastest-growing area within the Global Asthma Therapeutics Market. This significant growth is primarily driven by the enhanced efficacy and synergistic benefits offered by these treatments, which typically combine an inhaled corticosteroid with a long-acting beta-agonist in a single device. This approach simultaneously addresses both the inflammatory and bronchoconstrictive aspects of asthma pathophysiology, leading to improved patient outcomes and better symptom control. Moreover, the convenience of a single inhaler regimen substantially improves patient adherence and simplifies treatment management, reducing the complexity often associated with multiple medications. This shift is further supported by evolving clinical guidelines from institutions such as the British Thoracic Society and the National Institute for Health and Care Excellence, which increasingly recommend combination treatments for effective asthma management.

Regional Insights

North America leads the global asthma therapeutics market due to several distinct factors. The region exhibits a high prevalence of asthma, necessitating substantial demand for effective treatments. This is further supported by a robust healthcare infrastructure, facilitating access to advanced medical technologies and comprehensive patient care. The significant presence of major pharmaceutical companies, coupled with their substantial investments in research and development, drives innovation in asthma therapies, including novel biologics and combination treatments. Additionally, a well-established regulatory framework, exemplified by the stringent approval processes of the U.S. Food and Drug Administration (FDA), ensures the safety and efficacy of new drugs and devices, fostering market growth and patient confidence.

Recent Developments

• In May 2025, Sanofi and Regeneron announced the launch of a new Phase IIIb/IV clinical trial, AIM4, during an industry symposium at the American Thoracic Society (ATS) Congress. This trial is designed to evaluate whether earlier biologic intervention with dupilumab can offer superior outcomes for patients with uncontrolled moderate-to-severe asthma, compared to continuing with high-dose inhaled corticosteroids/long-acting beta-agonists (ICS/LABA). The study will randomize 250 patients, aiming to reassess the current stepwise approach to asthma care and potentially establish dupilumab as a more effective early treatment option in the global asthma therapeutics market.

• In January 2025, Kinaset Therapeutics, a clinical-stage biopharmaceutical company, announced that the United States Food and Drug Administration (FDA) accepted its Investigational New Drug (IND) application for frevecitinib (KN-002). This novel inhaled dry powder therapeutic is being developed for patients whose asthma remains inadequately controlled by standard-of-care inhaled maintenance therapies. Kinaset Therapeutics plans to initiate a Phase 2b dose-ranging trial in mid-2025 to evaluate the efficacy and safety of frevecitinib. Early Phase 1b study results indicated that frevecitinib significantly reduced airway inflammation, suggesting its potential as a targeted asthma treatment within the global asthma therapeutics market.

• In May 2024, RaeSedo, a biotechnology company, presented its pioneering approach to asthma treatment as a showcase company at the American Thoracic Society (ATS) Respiratory Innovation Summit. This involved significant milestones in developing its novel therapeutic, C940, for asthma and other lung diseases. The company successfully aerosolized C940 for inhalation delivery through an inexpensive device, demonstrating its potential in preclinical studies to reduce inflammation, mucus production, and airway hyperresponsiveness in asthma models. These advancements were supported by collaborations with partners, including Lovelace Biomedical and Genscript, for toxicology studies and production.

• In March 2024, AstraZeneca Pharma India Limited and Mankind Pharma Limited formed a strategic partnership to enhance the accessibility of asthma treatments across India. This collaboration aims to address the significant burden of asthma in the country by leveraging AstraZeneca's expertise in respiratory medications and Mankind Pharma's extensive distribution network. Under the terms of the agreement, Mankind Pharma will exclusively distribute AstraZeneca's budesonide and formoterol fumarate dihydrate combination, marketed under the brand name Symbicort, in India. AstraZeneca will retain the intellectual property rights, ensuring quality and adherence to global standards for this essential asthma therapeutic.

Key Market Players

• Teva Pharmaceutical Industries Ltd.
• GSK plc.
• Merck & Co., Inc.
• F. Hoffmann-La Roche Ltd.
• AstraZeneca plc.
• Boehringer Ingelheim International GmbH
• Sanofi S.A.
• Koninklijke Philips N.V.
• Becton, Dickinson and Company
• Sunovion Pharmaceuticals, Inc.

Report Scope:

In this report, the Global Asthma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Asthma Therapeutics Market, By Drug Class:

o   Anti-inflammatory

o   Combination Therapy

o   Bronchodilators

• Asthma Therapeutics Market, By Product:

o   Inhalers

o   Nebulizers

• Asthma Therapeutics Market, By Route of Administration:

o   Oral

o   Inhaled

o   Others

• Asthma Therapeutics Market, By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Asthma Therapeutics Market.

Available Customizations:

Global Asthma Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Asthma Therapeutics Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]